Skip to main content

Funding Opportunities

The College of Veterinary Medicine at NC State University and the Duke Cancer Institute have released their third annual joint funding opportunity to support pilot projects in comparative oncology. Applications that translate laboratory discoveries into diagnostic, prognostic, or therapeutic applications will be accepted to be considered for funding. Please see funding opportunity details below.

2018 Funding Opportunity Details

Request for Applications 

Online Application


Application Deadline: Friday, March 30, 2018

2017 Awarded Pilot Projects (in no specific order):

  • A Phase II Clinical Trial and Pharmacodynamics Study of CP-DOX in Dogs (DCI-Ashutosh Chilkoti, PhD; NCSU-Steven Suter, DVM, PhD, Diplomate ACVIM) 
  • A Mouse to Dog to Human (MDH) Drug Discovery Pipeline (DCI-William Eward, MD, DVM; NCSU-Matthew Breen, PhD) 
  • Investigating the Dog as a Preclinical Model for Melanoma Therapy Targeting the Long Non-Coding RNA SAMMSON (DCI-Shiaowen David Hsu, MD, PhD; NCSU-Jennifer Luff, VMD, PhD)
  • Comparative Analysis of the Impact of BRAF Mutations in Bladder Cancer – A Marker of Advancing Disease? (DCI- Brant Inman, MD; NCSU-Matthew Breen, PhD)
  • Imaging Cycling Hypoxia in Canine Tumors During Radiotherapy Dosing (DCI- Xiaofeng Steve Zhang, PhD; NCSU-Hiroto Yoshikawa, DVM, PhD)

2016 Awarded Pilot Projects (in no specific order):

  • A Phase 1 Clinical Trial of CP-DOX in Dogs: A Novel Nanoparticle Formation of an Old Drug (DCI-Ashutosh Chilkoti, PhD; NCSU-Steven Suter, PhD)
  • Development of a Personalized Medicine Pipeline for Treatment of Sarcomas (DCI-William Eward, MD, DVM; NCSU-Matthew Breen, PhD)
  • A Cross Species Genomic Analysis of Osteosarcoma: Implications for Novel Therapeutic Approaches (DCI-William Eward, MD, DVM; NCSU-Matthew Breen, PhD)
  • Identification of Carcinogen-Induced Mutational Signatures in Human and Canine Bladder Cancer (DCI-Brant Inman, MD; NCSU-Matthew Breen, PhD)